Subscribe To
Twist bioscience, eleven therapeutics create synthetic viral rna molecules to develop antiviral vaccines, therapeutics
Twist Bioscience Corp (NASDAQ: TWST) and Eleven Therapeutics have created a replicon tool that could be used for studying viral ...
February 7, 2022, 10:09 am
Twist bioscience, eleven therapeutics create synthetic viral rna molecules to develop antiviral vaccines, therapeutics
Twist Bioscience Corp (NASDAQ: TWST) and Eleven Therapeutics have created a replicon tool that could be used for studying viral ...
February 7, 2022, 10:09 am
Twist bioscience, eleven therapeutics create synthetic viral rna molecules to develop antiviral vaccines, therapeutics
Twist Bioscience Corp (NASDAQ: TWST) and Eleven Therapeutics have created a replicon tool that could be used for studying viral ...
February 7, 2022, 10:09 am
Bionano genomics is interesting as genome testing scales upwards
BNGO Stock is a play in the burgeoning gene sequencing market at scale, not at home. That's worth understanding and potentially purchasing....
January 25, 2022, 3:45 pm
Bionano genomics is interesting as genome testing scales upwards
BNGO Stock is a play in the burgeoning gene sequencing market at scale, not at home. That's worth understanding and potentially purchasing....
January 25, 2022, 3:45 pm
Bionano genomics is interesting as genome testing scales upwards
BNGO Stock is a play in the burgeoning gene sequencing market at scale, not at home. That's worth understanding and potentially purchasing....
January 25, 2022, 3:45 pm
Uniqure shares fall after clinical update from huntington's disease gene therapy trial
UniQure NV (NASDAQ: QURE) announced initial observations on the first four patients enrolled in the lower-dose cohort of Phase 1/2 trial of AMT-130...
December 16, 2021, 1:10 pm
Uniqure shares fall after clinical update from huntington's disease gene therapy trial
UniQure NV (NASDAQ: QURE) announced initial observations on the first four patients enrolled in the lower-dose cohort of Phase 1/2 trial of AMT-130...
December 16, 2021, 1:10 pm
Uniqure shares fall after clinical update from huntington's disease gene therapy trial
UniQure NV (NASDAQ: QURE) announced initial observations on the first four patients enrolled in the lower-dose cohort of Phase 1/2 trial of AMT-130...
December 16, 2021, 1:10 pm